Comparison of rates of dementia among older adult recipients of two, one, or no vaccinations

Timothy L Wiemken, Joanne Salas, John E Morley, Daniel F Hoft, Christine Jacobs, Jeffrey F Scherrer, Timothy L Wiemken, Joanne Salas, John E Morley, Daniel F Hoft, Christine Jacobs, Jeffrey F Scherrer

Abstract

Background: Multiple types of vaccinations are associated with lower risk for dementia, but it is not known if receiving more than one vaccination type is associated with a greater decrease in incident dementia as compared with receiving only one type. We determined if dementia risk is lowest in patients who receive both herpes zoster (HZ) and tetanus, diphtheria, pertussis (Tdap) vaccinations as compared with receipt of only one or the other type of vaccination.

Methods: Primary analysis in a Veterans Health Administration (VA) cohort was replicated in private sector medical claims data. Eligible patients were ≥65 years of age and free of dementia for 2 years prior to baseline (VHA n = 80,070; MarketScan n = 129,200). At index, patients either had both HZ and Tdap, only HZ, only Tdap, or neither vaccination. Confounding was controlled with generalized boosted propensity scores and inverse probability of treatment weighting. Competing risk (VHA) and Cox proportional hazard (MarketScan) models estimated the association between vaccination status and incident dementia.

Results: VHA patients' mean age was 76.8 ± 7.6 years, 4.4% were female and 90.9% were White, and MarketScan patients' mean age was 70.5 ± 5.9 and 65.4% were female. In both cohorts, having both HZ and Tdap vaccinations compared with no vaccination was significantly associated with lower dementia risk (VHA HR = 0.50; 95% CI: 0.43-0.59; MarketScan HR = 0.58; 95% CI: 0.38-0.89). In both cohorts, compared with neither vaccination, patients with only one or the other vaccination types had a significantly lower risk for dementia. Incident dementia was lower in patients with both vaccinations versus only one vaccination type.

Conclusions and relevance: Receiving two types of vaccinations versus one type was associated with lower dementia risk. Vaccinations may have non-specific associations with incident dementia. Low cost and accessible, common adult vaccinations may be an overlooked intervention for reducing dementia risk.

Keywords: cohort; dementia; epidemiology; infectious disease; vaccination.

Conflict of interest statement

The authors declare no conflicts of interest.

© 2021 The Authors. Journal of the American Geriatrics Society published by Wiley Periodicals LLC on behalf of The American Geriatrics Society.

Figures

FIGURE 1
FIGURE 1
Results from weighted competing risk (VHA) and Cox proportional hazard (MarketScan) models estimating the association (HR [95% CI]) of Tdap, HZ, and Tdap + HZ vaccinations and incident dementia

References

    1. Abbott A. Are infections seeding some cases of Alzheimer's disease? Nature. 2020;587(7832):22‐25.
    1. Rubin K, Glazer S. The pertussis hypothesis: Bordetella pertussis colonization in the pathogenesis of Alzheimer's disease. Immunobiology. 2017;222(2):228‐240.
    1. Tsai MC, Cheng WL, Sheu JJ, et al. Increased risk of dementia following herpes zoster ophthalmicus. PLoS One. 2017;12(11):e0188490.
    1. Bae S, Yun SC, Kim MC, et al. Association of herpes zoster with dementia and effect of antiviral therapy on dementia: a population‐based cohort study. Eur Arch Psychiatry Clin Neurosci. 2020;271:987‐997.
    1. Chen VC, Wu SI, Huang KY, et al. Herpes zoster and dementia: a nationwide population‐based cohort study. J Clin Psychiatry. 2018;79(1):16m11312.
    1. Honjo K, van Reekum R, Verhoeff NP. Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease? Alzheimers Dement. 2009;5(4):348‐360.
    1. Lövheim H, Gilthorpe J, Johansson A, Eriksson S, Hallmans G, Elgh F. Herpes simplex infection and the risk of Alzheimer's disease: a nested case‐control study. Alzheimers Dement. 2015;11(6):587‐592.
    1. Sipila PN, Heikkila N, Lindbohm JV, et al. Hospital‐treated infectious diseases and the risk of dementia: a large, multicohort, observational study with a replication cohort. Lancet Infect Dis. 2021;21:1557‐1567.
    1. Verreault R, Laurin D, Lindsay J, Serres GD. Past exposure to vaccines and subsequent risk of Alzheimer's disease. CMAJ. 2001;165(11):1495‐1498.
    1. Tyas SL, Manfreda J, Strain LA, Montgomery PR. Risk factors for Alzheimer's disease: a population‐based, longitudinal study in Manitoba, Canada. Int J Epidemiol. 2001;30(3):590‐597.
    1. Scherrer JF, Salas J, Wiemken TL, Jacobs C, Morley JE, Hoft DF. Lower risk for dementia following adult tetanus, diphtheria and pertussis (Tdap) vaccination. J Gerontol A Biol Sci Med Sci. 2021;76(8):1436‐1443.
    1. Liu JC, Hsu YP, Kao PF, et al. Influenza vaccination reduces dementia risk in chronic kidney disease patients: a population‐based cohort study. Medicine (Baltimore). 2016;95(9):e2868.
    1. Luo CS, Chi CC, Fang YA, Liu JC, Lee KY. Influenza vaccination reduces dementia in patients with chronic obstructive pulmonary disease: a nationwide cohort study. J Investig Med. 2020;68(4):838‐845.
    1. Wiemken TL, Salas J, Hoft DF, Jacobs C, Morley JE, Scherrer JF. Dementia risk following influenza vaccination in a large veteran cohort running head: influenza vaccination and dementia. Vaccine. 2021;39:5524‐5531.
    1. Centers for Disease Control . National and State‐Level Place of Flu Vaccination among Vaccinated Adults in the United States, 2014–15 Flu Season. Accessed August 4, 2021.
    1. Rutschman AS, Wiemken TL. Re‐examining vaccine staggering within hesitancy frameworks. Front Immunol. 2021;12:662814.
    1. Hostetter J, Schwarz N, Klug M, Wynne J, Basson MD. Primary care visits increase utilization of evidence‐based preventative health measures. BMC Fam Pract. 2020;21(1):151.
    1. Hachem CY, Kramer JR, Kanwal F, El‐Serag HB. Hepatitis vaccination in patients with hepatitis C: practice and validation of codes at a large Veterans Administration Medical Centre. Aliment Pharmacol Ther. 2008;28(9):1078‐1087.
    1. Harding BN, Floyd JS, Scherrer JF, et al. Methods to identify dementia in the electronic health record: comparing cognitive test scores with dementia algorithms. Healthc (Amst). 2020;8(2):100430.
    1. Scherrer JF, Morley JE, Salas J, Floyd JS, Farr SA, Dublin S. Association between metformin initiation and incident dementia among African American and white Veterans Health Administration patients. Ann Fam Med. 2019;17(4):352‐362.
    1. Scherrer JF, Salas J, Floyd JS, Farr SA, Morley JE, Dublin S. Metformin and sulfonylurea use and risk of incident dementia. Mayo Clin Proc. 2019;94(8):1444‐1456.
    1. Salas J, Morley JE, Scherrer JF, et al. Risk of incident dementia following metformin initiation compared with noninitiation or delay of antidiabetic medication therapy. Pharmacoepidemiol Drug Saf. 2020;29(6):623‐634.
    1. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496‐509.
    1. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661‐3679.
    1. Haneuse S, VanderWeele TJ, Arterburn D. Using the E‐value to assess the potential effect of unmeasured confounding in observational studies. JAMA. 2019;321(6):602‐603.
    1. Lipsitch M, Tchetgen ET, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010;3:383‐388.
    1. Almeida‐Meza P, Steptoe A, Cadar D. Markers of cognitive reserve and dementia incidence in the English Longitudinal Study of Ageing. Br J Psychiatry. 2020;1‐9:1.
    1. Ackerson B, Qian L, Sy LS, et al. Completion of the two‐dose recombinant zoster vaccine series in adults 50 years and older. Vaccine. 2021;39(6):926‐932.
    1. Jain A, van Hoek AJ, Boccia D, Thomas SL. Lower vaccine uptake amongst older individuals living alone: a systematic review and meta‐analysis of social determinants of vaccine uptake. Vaccine. 2017;35(18):2315‐2328.
    1. Fogelberg S, Lamb F, Gronlund O, et al. Differential uptake of herpes zoster vaccination associated with socioeconomic status: a population‐based study in Stockholm County, Sweden. Pharmacoepidemiol Drug Saf. 2018;27(11):1159‐1165.
    1. Lu PJ, Hung MC, Srivastav A, Williams WW, Dooling KL. Shingles vaccination of U.S. adults aged 50‐59 years and ≥ 60 years before recommendations for use of recombinant zoster vaccine. Am J Prev Med. 2020;59(1):21‐31.
    1. Roblin DW. Validation of a neighborhood SES index in a managed care organization. Med Care. 2013;51(1):e1‐e8.
    1. Wiemken TL, Salas J, Hoft DF, Jacobs C, Morley JE, Scherrer JF. Dementia risk following influenza vaccination in a large veteran cohort. Vaccine. 2021;39:5524‐5531.
    1. Shuvo S, Hagemann T, Hohmeier K, Chiu CY, Ramachandran S, Gatwood J. The role of social determinants in timely herpes zoster vaccination among older American adults. Hum Vaccin Immunother. 2021;17(7):2043‐2049.
    1. Scherrer JF, Salas J, Wiemken TL, Hoft DL, Jacobs C, Morley JE. Impact of herpes zoster vaccination on incident dementia: a retrospective study in two patient cohorts. PLoS One. Forthcoming. 2021;16(11):e0257405.
    1. Benn CS, Netea MG, Selin LK, Aaby P. A small jab ‐ a big effect: nonspecific immunomodulation by vaccines. Trends Immunol. 2013;34(9):431‐439.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe